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Abstract
Public health organizations, such as the Centers for Disease Control and Prevention (CDC), are 
increasingly recommending the use of N95 filtering facepiece respirators (FFRs) in health care 
settings. For infection control purposes, the usual practice is to discard FFRs after close contact 
with a patient (“single use”). However, in some situations, such as during contact with 
tuberculosis patients, limited FFR reuse (i.e., repeated donning and doffing of the same FFR by 
the same person) is practiced. A related practice, extended use, involves wearing the same FFR for 
multiple patient encounters without doffing. Extended use and limited FFR reuse have been 
recommended during infectious disease outbreaks and pandemics to conserve FFR supplies. This 
commentary examines CDC recommendations related to FFR extended use and limited reuse and 
analyzes available data from the literature to provide a relative estimate of the risks of these 
practices compared to single use.
Analysis of the available data and the use of disease transmission models indicate that decisions 
regarding whether FFR extended use or reuse should be recommended should continue to be 
pathogen- and event-specific. Factors to be included in developing the recommendations are the 
potential for the pathogen to spread via contact transmission, the potential that the event could 
result in or is currently causing a FFR shortage, the protection provided by FFR use, human 
factors, potential for self-inoculation, the potential for secondary exposures, and government 
policies and regulations. While recent findings largely support the previous recommendations for 
extended use and limited reuse in certain situations, some new cautions and limitations should be 
considered before issuing recommendations in the future. In general, extended use of FFRs is 
preferred over limited FFR reuse. Limited FFR reuse would allow the user a brief respite from 
extended wear times, but increases the risk of self-inoculation and preliminary data from one study 
suggest that some FFR models may begin to lose effectiveness after multiple donnings.
Background
The Centers for Disease Control and Prevention (CDC)—including the National Institute for 
Occupational Safety and Health (NIOSH), as well as the Occupational Safety and Health 
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Administration (OSHA) and the Food and Drug Administration (FDA)—develop 
regulations and/or recommendations for the use of respiratory protection in health care 
settings, and each agency plays a different role which impacts the use of them in health care. 
CDC develops recommendations for the use of respirators to reduce the spread of disease in 
health care settings. NIOSH certifies respirators and develops recommendations on the use 
of respiratory protection in health care workplaces to protect workers. OSHA develops and 
enforces workplace regulations on respiratory protection. FDA clears the sale of certain 
types of respirators as medical devices.
The most commonly used type of respirator in health care settings are NIOSH certified N95 
filtering facepiece respirators (FFRs). These devices are disposable, tight-fitting air-
purifying respirators that have a filter efficiency of 95% or greater for a standard test 
aerosol.(1) FFRs are also used by workers in many industries to reduce the amount of 
harmful dusts and aerosols they inhale. Workers are expected to wear their FFR during all 
periods of exposure. However, there are times of non-exposure when workers need to 
remove their FFR (e.g., take a drink of water, use the restroom, or go on a rest break) or 
situations during use when their FFR must be replaced.
Employers have several options for FFR usage to handle these situations. During “single 
use,” users put on (“don”) a new FFR each time they need one and discard their used FFR 
each time they take it off (“doff”). Another option is commonly referred to as “FFR reuse.” 
Reuse involves donning and doffing the same FFR more than once until the FFR is 
discarded. Employers benefit from FFR reuse compared to single use by extending the 
lifetime of the FFR so that fewer need to be purchased. There is no specific restriction on the 
number of uses or donnings. Rather, historical guidance is focused on the length of time the 
FFR can be used and identifying situations when the FFR should be discarded. In general, 
NIOSH(2) specifies that the service life of all filters on NIOSH-approved respirators is 
limited by considerations of hygiene, damage, and breathing resistance and that any filter 
should be replaced if it becomes soiled, damaged, or causes noticeably increased breathing 
resistance. In workplaces that could produce high cumulative particulate filter loading (i.e., 
>200 mg), the service time for N95 FFRs should only be extended beyond 8 hr of use 
(continuous or intermittent) by performing an evaluation that demonstrates that continued 
use will not reduce the filter efficiency.
FFR Use in Health care
FFRs have been used in industrial settings such as construction, manufacturing, and mining 
since the 1970s. Starting in the 1990s, these devices found new applications in health care 
settings.(3) Initially, FFRs were recommended as the minimum level of protection to reduce 
exposure to infectious aerosols from patients with tuberculosis(4–7) Later, similar 
recommendations(8) were made for outbreaks and pandemics involving pathogens with 
potential for aerosol transmission.
FFR use in health care settings has unique challenges and risks. Unlike industrial settings, 
some models of NIOSH-certified FFRs (commonly called “surgical N95 respirators”) are 
also cleared for sale by the FDA as medical devices.(9) According to the FDA's 510(k) 
Premarket Notification Database, (10) the first clearance for a surgical N95 respirator 
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(product code = MSH) occurred in 1996, after FFRs were first recommended by CDC as the 
minimum level of protection for health care workers (HCWs) treating patients with 
tuberculosis(4) and NIOSH updated its certification requirements to create the N95 class of 
filters.(1) Most (22/31 = 71%) of the surgical N95 respirator models in the FDA database 
were cleared after 2005, which coincides with a period of increased interest in these types of 
products due to concerns about an infectious disease pandemic.
Because of the concerns that previously used FFRs may be contaminated with infectious 
material (i.e., act as a fomite), the factors that a health care employer considers in 
formulating FFR use policies (e.g., single vs. reuse) for its employees are also different from 
employers in industrial settings. Despite this concern, FFRs are reused under certain 
conditions in health care.(11) In the health care context, reuse is defined as a HCW donning 
the same FFR for a series of close patient contacts and doffing it at the end of each of the 
close patient contacts before it is discarded. Even when FFR reuse is practiced or 
recommended (discussed in the next section), restrictions are in place (e.g., discard when 
FFR is contaminated or damaged, becomes difficult to breathe through, and so on) which 
limits the number of times the same FFR is reused. Thus, FFR reuse is sometimes referred to 
as “limited FFR reuse.” Options for limited FFR reuse were provided when FFRs were first 
introduced as the minimum level of respiratory protection for HCWs in close contact with 
patients with tuberculosis.(4–6)
Another related FFR use practice, termed “extended use,” involves donning a FFR and 
wearing it for multiple patient encounters without doffing and redonning between patient 
visits. Thus, the same FFR is worn continuously (for up to several hours) across multiple 
patient encounters before it is doffed. This practice is only practical when bundled with the 
practice of cohorting, which involves locating patients with a common diagnosis in the same 
unit, ward, or zone. Extended use can be implemented separately from reuse (i.e., like single 
use, discard the FFR once it is doffed) or combined with reuse. Compared to single use and 
reuse, recommendations for extended use in health care are fairly recent. The first time 
extended use of FFRs was identified as an option was during the 2009 H1N1 pandemic.(12)
Both extended use and limited reuse of FFRs allow the employer to reduce its consumption 
of FFRs, prolonging existing supplies during a pandemic or respiratory pathogen outbreak or 
to save money and reduce waste during day-to-day operations (e.g., close contact with 
tuberculosis patients) by using fewer FFRs,(13) similar to the benefits found for industrial 
settings. This commentary examines recommendations related to extended use and limited 
reuse of FFRs in health care. Key scientific and policy issues are highlighted along with 
considerations for policy makers to weigh when making decisions on whether to recommend 
extended use and/or limited reuse of FFRs during routine health care situations and for 
public health emergencies involving respiratory pathogens that have the potential for aerosol 
transmission. Finally, key knowledge gaps are discussed to identify additional data needs 
that could enhance understanding of the risks for transmission of diseases associated with 
FFR extended use and limited reuse.
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Current and Past FFR Extended Use and Limited Reuse Recommendations
Table I summarizes past and current recommendations for extended use and limited reuse of 
FFRs. CDC recommendations were selected for this analysis because of their widespread 
recognition in health care. In 2007, CDC published general infection control guidance for 
isolation precautions, which included a list of all pathogens and medical procedures in 
which respiratory protection was recommended.(14) For certain pathogens affecting defined 
populations (e.g., TB) or infectious agents of special interest to health care (e.g., 
epidemiologically important organisms such as severe acute respiratory syndrome (SARS)] 
and influenza), CDC publishes detailed specialized infection control guidance. For this 
analysis, we selected all of the respiratory pathogens in which specialized infection control 
guidance was published as either interim or final recommendations and included the use of 
respiratory protection (N95 FFR or higher). This strategy provided a diversity of respiratory 
pathogens for analysis. These situations include two recent outbreaks/pandemics (2004 
SARS and 2009 H1N1 flu), two routine situations (TB and seasonal influenza), and two 
pathogens of concern (Avian Influenza A (H5N1) and Avian Influenza A (H7N9)).
Cost can be a consideration for adopting extended use and limited reuse practices as it was 
in adopting the recommendation to allow limited reuse of FFRs when working in close 
contact with TB patients. However, the CDC recommendations on limited reuse and 
extended use have primarily considered the specific pathogens involved and the specific 
characteristics of the event. The first key factor is whether contact transmission is possible 
for the pathogen. Contact transmission of pathogens occurs through direct or indirect contact 
with the patient or the patient's environment via blood or body fluids (e.g., respiratory 
secretions). For pathogens in which contact transmission (e.g., fomites) is not a concern, 
limited reuse of FFRs has been determined to be a viable option. For TB, the CDC maintains 
that “a respirator classified as disposable can be reused by the same HCW as long as it 
remains functional and is used in accordance with local infection control procedures.” (15) 
Infection control guidelines for TB (14) recommend only airborne precautions; contact 
isolation precautions are only needed if extrapulmonary lesions are draining, which occurs 
rarely. Contact transmission of TB is thought to be highly unlikely.(16)
This contrasts with the recommendations for seasonal influenza where contact with 
contaminated surfaces and objects is considered a possible mode of transmission.(17) In 
situations where airborne precautions are recommended, and contact precautions are 
recommended or contact transmission is possible, the second key factor in the CDC 
recommendations is the likelihood of a localized shortage of the FFRs needed to protect 
HCWs during high-risk procedures. The use of FFRs for protection of HCWs during routine 
infectious disease procedures generally does not result in a FFR shortage, as evidenced by 
CDC's guidance to wear a FFR during aerosol generating procedures (AGPs) on patients 
diagnosed with seasonal influenza; this does not include an option for FFR extended use or 
reuse.(17)
CDC recommendations for Avian Influenza A (H7N9)(18) indicate that FFRs should be 
discarded after leaving the patient room or patient care area (i.e., “single use”). CDC 
recommendations for Avian Influenza A (H5N1)(19) do not specifically mention single use, 
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extended use, or limited reuse, but instead refer back to the general CDC infection control 
guidance(14) which specifies single use. These recommendations are consistent with the 
other four recommendations in Table I based on the potential for contact transmission of 
these pathogens and that FFR shortages are unlikely in the near-term.
However, during periods of high usage (e.g., public health emergencies such as an influenza 
pandemic(20) or widespread respiratory pathogen outbreak), supplies of FFRs can quickly 
become depleted because most hospitals maintain only a small inventory of FFRs. Not 
surprisingly, shortages were reported at the hospital level during both the 2004 SARS 
outbreak and the 2009 H1N1 influenza pandemic.(21–23) In a recent evaluation of respiratory 
protection programs in California hospitals, it was reported that half of the hospital 
managers interviewed (n = 48) reported shortages of FFRs during the 2009 H1N1 outbreak 
due to increased demand and supplier lag time in filling orders.(11) During the 2004 SARS 
and 2009 H1N1 events, recommendations were made allowing the option for extended use 
and limited reuse, although both recommendations acknowledged situations in which these 
strategies would not be appropriate.
For SARS, CDC stated in its interim guidance that “health care facilities may consider reuse 
as long as the device has not been obviously soiled or damaged (e.g., creased or torn)” and 
“if a sufficient supply of respirators is not available.”(24) The recommendation recognized 
the importance of preventing contamination through contact with infectious material on the 
outside of the respirator. CDC also addressed concerns about a shortage of FFRs during the 
2009 H1N1 flu pandemic with supply-conserving strategies for hospitals that included the 
possibility of extended use and limited reuse of FFRs, with extended use preferred over 
limited reuse.(12,25) Reuse of FFRs was reported to occur quite often in California hospitals 
during 2009 H1N1 as either a response to shortages or as standard practice; 81% of survey 
respondents indicated that their hospital had a plan to implement reuse, while only 12.5% 
indicated plans to apply extended use.(11)
Scientific Evidence On FFR Extended Use and Limited Reuse
As shown in Table I and discussed above, prior and current CDC recommendations made 
for FFR extended use and reuse were largely based on the type of infection control 
precautions or transmission mode(s) associated with that pathogen and whether shortages of 
FFRs were observed or anticipated. Those recommendations were based upon the data 
available at that time, which often lacked evidence to answer key questions regarding the 
effectiveness of extended use or limited reuse and the risk of disease transmission from 
handling potentially contaminated FFRs. In 2006, the Institute of Medicine (IOM) 
addressed (26) the reusability of facemasks, and summarized the data available to support 
previous recommendations. The committee agreed with the previous CDC guidance and 
recommended that “avoiding contamination [of FFRs] will allow for limited reuse.” The 
IOM also identified key knowledge gaps that served as a catalyst for increasing awareness 
of the research needs.
Since publication of the IOM report, numerous research groups have attempted to address 
some of these knowledge gaps. In the following sections, we discuss studies published since 
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2006 that address key areas of FFR extended use and reuse, including FFR protection, 
human factors (e.g., physiological/psychological effects), self-inoculation, and secondary 
exposures (e.g., from particle reaerosolization and co-contaminants). Some earlier studies 
(pre-2006) are also discussed to provide context where needed. The purpose of this analysis 
is to improve the scientific basis for future recommendations for employers in health care 
settings to consider when implementing FFR extended use and/or limited reuse. For each of 
the issues below, a qualitative assessment of the risks of extended use and limited reuse 
versus single use is presented (see Table II).
FFR Protection
One possible concern with FFR extended use and reuse is that extending the useful life of a 
FFR could reduce its protective effectiveness (i.e., when worn properly and used in a 
complete respiratory protection program it provides exposure reduction consistent with the 
assigned protection factor for this class of respirator). The protection provided by a properly 
used FFR results primarily from a combination of its ability to filter out (remove) biological 
aerosols from the inhalation air stream of the wearer and seal tightly to the face (i.e., “fit”). 
Each of these concerns has been studied (to some extent) or can be assessed using existing 
data.
Filter Media—Most N95 FFRs contain a polypropylene electret filtering medium within 
the layers of a FFR (Figure 1). The electret filtering medium has been shown to capture and 
retain a majority of airborne biological particles compared to the layers next to the face and 
farthest from the face, although particle size could affect particle deposition location.(27,28) 
Electrets and other similar types of nonwoven air filter media are not unique to FFRs.(29) 
They are commonly found in various dust collection systems (e.g., vacuum cleaners, clean 
rooms, and home heat ventilation and air conditioning (HVAC) systems). Recommended 
replacement life for electret filters in air cleaning systems is typically 3 months of normal 
use, as the fundamental mechanisms (diffusion, interception, impaction, electrostatic, and so 
on) of these types of filters do not readily degrade over time with normal use.
Only a few studies have been done to verify FFR performance in extended use or reuse type 
scenarios. Moyer and Bergman(30) conducted a laboratory evaluation of the intermittent use 
(short-term use once per week) of N95 filters over several months. Filtration efficiency was 
reduced to below 95% for filters from 2 of the 3 manufacturers after 9 and 13 weeks of 
simulated reuse. Researchers at the Institut de recherché Robert-Sauvé en santé et en 
sécurité du travail (IRSST) validated the long-term filter performance of a single N95 FFR 
model. (31) For inert particles below 200 nm, filter efficiency levels remained above 97.3%, 
even after 5 hr of particle loading (i.e., continuous use). Not surprisingly, another study 
found that samples from 19 of 21 N95 FFR models stored for up to 10 years had expected 
levels of filtration performance.(32)
Fit—Fit is a measurement of the efficacy of the seal between the FFR and the face of the 
wearer. Components of the FFR, such as straps, face seal material, shape, and adjustable 
nose bands influence FFR fit. Several studies have analyzed strap performance and fit for 
multiple donnings of FFRs. Roberge et al. measured the restorative forces of straps for five 
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simulated donnings and reported reduction in the strap load for each successive donning 
with the majority of the reduction occurring after the first donning.(33) However, the FFR 
model with the lowest restorative strap performance load was still able to pass fit-testing. 
Bergman et al. examined the effect of FFR reuse on fit by measuring the fit factors of 6 FFR 
models donned by 10 subjects up to 20 times with wear times of approximately 2 min 
between each donning.(34) FFR fit gradually decreased over multiple consecutive donnings; 
however, good fit was observed for some subjects on some models even after 20 donnings. 
The best levels of fit were observed for the first five donnings, likely because of the 
relatively little wear on FFR components (e.g., head straps and nosepieces) compared with 
later donnings.
It was concluded from that study that five donnings could be performed before fit factors 
started to drop below 100. Catastrophic failure of the FFR (e.g., complete head strap 
breakage, nosepiece becomes damaged, and so on) should have no effect on risk, if users 
diligently perform device inspection procedures required during the FFR donning process. 
Fit of FFRs is also a concern for extended use where the FFR may become wet and 
deformed due to moist exhaled breath and facial perspiration. Hauge et al. measured real-
time fit while HCWs performed three 10-min simulated patient care scenarios. It was 
determined that initial fit was predictive of fit during the tasks as the five subjects with 
initial fit factors greater than 200 registered simulated workplace protection factors greater 
than 400, and the three subjects with initial fit factors less than 200 had simulated workplace 
protection factors ranging from 132 to 326.(35) Although the tasks were only a combined 30 
min, the study design could be considered an extended use scenario covering three patient 
encounters.
Workplace Protection Factors—Few studies in health care settings measure workplace 
protection factors (WPF). WPF is a measure of the protection provided by a properly 
functioning respirator when correctly worn and used in the workplace and is determined as 
the ratio of the particle concentration outside the respirator over the particle concentration 
inside the respirator. Infectious bioaerosols are hard to detect and differentiate from non-
infectious bioaerosols.(36) Furthermore, assuring compliance during all periods of exposure 
in the health care setting is challenging.(37) Several studies in other workplaces have 
assessed protection over extended periods of continuous use by measuring the WPFs: up to 
224 min in a steel foundry(38); 172 min in a concrete factory (39); and 60 min on farms.(40) 
All three studies concluded that the N95 FFRs provided levels of protection consistent with 
expectations (i.e., protection factors were ≥ the assigned protection factor of 10), with 
reported geometric mean WPF values ranging from 18 to 223. No evidence of reduced 
protection as a function of time was noted in these studies. The aerosol challenge 
encountered at the farm locations consisted of biological aerosols such as endotoxins and 
fungal spores which are more closely related to the bioaerosols in a hospital than to the dust 
encountered at the foundry and concrete factory.
Summary—Overall, the scientific studies provide evidence that extended use is unlikely to 
reduce the protection afforded by a FFR (see Table II) and support the CDC TB infection 
control guidance which states in the Frequently Asked Questions section, “Disposable 
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respirators can be functional for weeks to months.” However, as noted in Table II, some 
additional cautions may apply for reuse. Reuse involves multiple repeated uses (donnings) 
of the same device, and it is possible that some components (straps, nose clips, and so on) 
could begin to degrade over time and reduce protection. These effects are likely specific to 
each model of FFR, but the only study published(34) to date on this topic suggests that 
limiting FFR reuse to no more than five donnings or reuses would provide an adequate 
safety margin.
Human Factors
One of the consequences of extended use is the need to wear the FFR continuously for up to 
several hours, compared with single use or reuse in which the FFR would only be worn 
during the period of close contact with the patient (typically less than 15–20 min). Thus, 
questions have been raised regarding the safety of long-term FFR use and, if safe, how long 
HCWs can physiologically and psychologically tolerate extended use.
NIOSH researchers found that FFR use caused no or minimal increases in heart rate, 
respiratory rate, and transcutaneous carbon dioxide as well as no differences in oxygen 
saturation on test subjects during 1 hr of low-moderate treadmill exercise when compared 
with wearing no respirator (control).(41–43) They also reported that 2 hr of continuous FFR 
use at low-moderate work rate did not cause a change in core body temperature,(42) and 
there was no significant increase in FFR deadspace heat or humidity after the first hour.(44) 
Taken together, these studies suggest that FFR use for 1–2 hr should cause minimal 
physiological stress to individuals medically cleared to wear FFRs.
A study by researchers affiliated with Department of Veterans Affairs reported how long 27 
HCWs could tolerate multiple bouts of 2-hr-long extended use periods, interspersed with 
15–30 min breaks.(45) Median tolerance times of 6.6 hr and 5.8 hr were reported for the two 
FFR models without exhalation valves. Only 16 and 18 of the 27 subjects using those two 
models were able to complete all four 2-hr use periods of continuous use; the most reported 
reason for stopping use was head and facial discomfort (e.g., heat). In a follow-up analysis 
of the same data, it was concluded that FFR discomfort negatively affects respirator 
tolerance over time, but respirator intolerance is not associated with perceived self-reported 
exertion.(46)
Although the number of participants was small, a recent study reports greater tolerance of 
extended use of FFRs among HCWs.(47) They reported that 9 of 10 study participants 
(nurses) were willing to wear FFRs for the entirety of two full 12-hr shifts, stopping only to 
eat and drink, because it was the end of their shift, or because the FFR was too 
uncomfortable. The nurses tolerated FFR continuous wear for an average of 223 min on day 
1 and 145 min on day 2 and experienced little physiological burden; however, discomfort 
increased with time, and the nurses reported feeling more short of breath the longer they 
wore respiratory protection. Transcutaneous carbon dioxide levels increased over time, but 
were not clinically relevant in that carbon dioxide levels did not reach the requirement for 
clinically defined hypercapnia.
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A study conducted in a teaching hospital in Brazil considered changes in appearance and 
possible physical damage resulting from FFR reuse.(48) A new N95 FFR was distributed to 
each nurse once per month and reused as needed until the next new N95 FFR was provided. 
The researchers found that within 5 days, the majority of the distributed cone-shaped FFRs 
exhibited visible “wear and tear,” indicating possible physical damage (caused by folding 
them for storage in a pocket) and visible stains/dirt on the FFR interior and exterior surfaces. 
Although the performance of the respirators was not assessed, the data suggest that some 
models may be more suitable for reuse (e.g., those that fold easily) or that hospitals should 
enforce some restrictions on reuse (e.g., replace every 5 days, rather than every 30 days).
Overall, the available scientific studies provide evidence that HCWs will experience greater 
discomfort during periods of extended continuous wear of FFRs, but this discomfort will 
likely be tolerable for most HCWs. Continuous FFR use over extended periods of time up to 
12 hr is unlikely to harm workers (see Table II) who have been medically cleared for 
respirator use. Furthermore, because HCWs need to take occasional breaks during their 
work shift (e.g., to use the rest room, eat or drink, and so on) FFR extended use of greater 
than 4 consecutive hours is unlikely in most settings.
Self-Inoculation Hazard
One knowledge gap often cited against allowing FFR extended use and limited reuse is 
whether a FFR worn during close contact with an infected patient is likely to serve as a 
fomite. Historically, little data were available to assess the transfer potential of respiratory 
pathogens from the FFR to the hands of the HCW, resulting in the potential for self-
inoculation. Similar to other potential fomites (e.g., surfaces, medical devices, and 
stethoscopes(49)) assessing the level of risk of self-inoculation associated with touching a 
used FFR is complex. It is very difficult to trace a specific hospital-acquired infection to a 
particular object. Thus, while no studies have identified the use of a contaminated FFR as a 
source of infection, the possibility cannot be ruled out.
Nicas and Sun and Nicas and Jones have provided models for transmission of pathogens, 
including influenza, in health care settings.(50,51) Nicas and Sun considered fomite hazards 
of textile and nontextile surfaces and in room air to estimate the expected pathogen dose to a 
HCW's mucous membranes and respiratory tract.(51) Nicas and Jones modeled four 
influenza virus exposure pathways including fomite transmission. A similar approach is 
used below to estimate the potential fomite hazard of used FFRs. Factors that influence the 
risk of self-inoculation directly associated with handling a contaminated FFR include the 
quantity of respiratory pathogens deposited on the FFR surface (i.e., contamination levels), 
viability of the pathogen, transfer efficiency of the pathogen from FFRs to the hands of the 
wearer, and area of hand contact with the contaminated surface.
FFR Contamination Levels—There are no published studies that quantify the amount of 
pathogens on FFRs used in clinical settings. However, simple mathematical models can be 
used to provide some estimates. In one study, influenza aerosol concentration, breathing rate 
of the wearer, time of patient interaction/FFR use, and particle retention efficiency of the 
FFR were used as inputs to a linear model to estimate influenza contamination levels inside 
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and on the surface of the FFR (CFFR).(52) Using this model, an increase in any parameter 
results in higher levels of CFFR (i.e., total number of pathogens on the FFR). For a typical 
HCW scenario, using model input values estimated from the peer-reviewed literature, the 
model calculated that CFFR would be approximately 4500 influenza viruses given an 
influenza aerosol concentration of 12,000 viruses m–3, a breathing rate of 1.140 m3hr–1, a 
particle retention efficiency of the FFR of 0.991, and a 20-min patient interaction/FFR use 
time. The values for influenza aerosol concentration and wear time found in the literature 
varied more than other parameters used in the model. Thus, for extended use which involves 
longer wear times, the number of pathogens available for transfer to the hands is increased.
This model illustrates the need to take into account HCW procedures (e.g., AGPs) which can 
increase CFFR by up to 2200% and the potential for administrative controls such as source 
control of patients (e.g. asking patients to wear face-masks) which can reduce CFFR by up to 
71%.(53,54) In addition to administrative controls, the use of engineering controls such as 
local exhaust ventilation might reduce CFFR. Similarly, previous recommendations issued 
during the SARS outbreak suggested the use of a surgical mask or faceshield on top of a 
FFR to reduce CFFR(26); although subsequent work has identified a number of potential 
concerns, including regulatory compliance with this approach.(55) While developed for 
influenza, this model could be used to approximate CFFR resulting from any respiratory 
pathogen if estimates of the concentrations of the pathogen near the breathing zone of the 
HCW could be obtained.
Pathogen Survival—Given that FFRs can become contaminated with pathogens when 
used in close contact with infectious patients, the next factor under consideration is how 
long these pathogens can survive (remain infectious) and, for some types of 
microorganisms, grow (propagate) on the FFR surface. Some studies in the early 1990s 
found that under ideal conditions (e.g., humidity >78%), fungi and certain bacteria could 
grow on filters made of cellulose because they are capable of digesting cellulose.(56,57) 
However, modern (post-1995) FFRs are made of polypropylene, which cannot serve as a 
nutrient for bacteria.(58)
Studies confirmed that surrogates for TB were not able to grow on polypropylene-based 
filter media, even under incubation conditions.(58–61) Although bacteria were found to 
survive for several days, this was not considered a concern because contact transmission for 
TB is considered unlikely (see Table I). These studies lent support for the FFR reuse 
guidance being drafted at that time.
Respiratory viruses have received more recent attention. While growth is not an issue 
because these pathogens require a host organism to propagate, their persistence or survival 
on surfaces is a concern. In general, the evidence indicates that viruses are more persistent 
on nonporous substrates compared with porous materials such as FFRs. Bean et al. reported 
laboratory-grown influenza A and influenza B survived for 24–48 hr on hard, nonporous 
surfaces but survived for <8-12 hr on porous substrates.(62) Similarly, another study(63) 
found that influenza remained viable for 8 hr on FFR samples, but infectivity dropped below 
detection limits at <24hr.
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However, Tiwari et al. examined the persistence of two avian respiratory viruses including 
influenza H13N7 on various substrates and although they found that both viruses survived 
longer on nonporous surfaces than on porous ones, the viruses remained active for up to 6 
days.(64) In one laboratory study, pH1N1 was detected on FFRs for up to 6 days with an 
average of 90% reduction (1 log) in viability during this time period.(65) Similar findings 
were found using MS2 phage as a surrogate for respiratory viruses.(66) A surrogate for 
SARS coronavirus, transmissible gastroenteritis virus, was shown to remain viable for 24 hr 
on FFR samples with an estimated 99% (>2 log) reduction in titer.(67))
Another study found that inactivation of Φ6 bacteriophage spiked on a N95 FFR surface was 
highly sensitive to environmental conditions, with a ∼1 log reduction over 24 hr at 40% 
relative humidity versus ∼4 log reduction over 24 hr at 60% relative humidity.(68) Although 
it is difficult to generalize from these conflicting findings, it is clear that for reuse during a 
work shift with short storage times (< 1 hr) most of the trapped pathogen will remain viable. 
Some reduction in viability might occur for overnight (>12 hr) or weekend (>24 hr) storage 
depending upon storage conditions (temperature, humidity, light, and so on) and pathogen 
type and strain.
In many cases where pathogens remain persistent and pose a contact threat, cleaning and 
disinfection regimens are routinely used. For example, countertops, exam tables, and other 
surfaces of patient rooms are often cleaned when a patient is discharged. Research has been 
conducted on cleaning and disinfecting procedures for FFRs for possible reuse by the same 
HCW. Although the results appear to be promising, the practice is not currently 
recommended(69-72) and thus is not a viable solution at this time to reduce the fomite 
potential of a reused FFR.
Recent improvements in antimicrobial chemistries have allowed some manufacturers to 
begin incorporating these technologies into FFRs. There are now a few surgical N95 FFRs 
incorporating antimicrobial technologies (product code = ONT) that have been cleared by 
the FDA as medical devices.(9) Interestingly, one device has been cleared by the FDA with 
claims of 8 hr of continuous use. Unfortunately, none of these devices has been evaluated in 
the peer-reviewed literature for claims regarding their ability to reduce fomite potential. 
However, several studies(73–77) have looked at the ability of prototypes or devices, not 
cleared by FDA, that incorporate some type of antimicrobial chemistry in them to render 
trapped pathogens inactive over time (i.e., storage time between uses). These studies suggest 
that efficacy of antimicrobial FFRs for this application is dependent on the pathogen, 
antimicrobial agent, storage conditions, and specific test method used which makes 
generalization of findings difficult.(73,78–81) Although promising, the lack of conclusive 
evidence suggests that additional work is needed before FFRs incorporating antimicrobial 
technologies can be factored into FFR reuse recommendations.
Transfer Efficiency—Because FFRs can become contaminated with pathogens likely to 
remain infectious during typical extended use and reuse scenarios, the next factor to assess is 
the likelihood of pathogens transferring from the FFR to the hands of HCWs. Unfortunately, 
no studies exist that quantify the percentage of pathogen transferred from the FFR to the 
hands of HCWs. However, similar to estimating contamination levels, models can be used 
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where estimates of the key input parameters are available. A simple model for estimating the 
amount of pathogen transferred to the hands (Chand) of HCWs from contaminated FFRs uses 
CFFR (the number of pathogens on the FFR as discussed above), transfer efficiency of the 
pathogen (Et), and contact area of the hands (Ah) and the FFR (AFFR).
Unfortunately, no peer-reviewed sources are available on the transfer efficiency of relevant 
pathogens from a FFR to skin and others surfaces. However, an unpublished conference 
presentation reports the transfer efficiency of a bacterium, Bacillus atrophaeus, from FFRs 
to synthetic skin as 0.005% and 0.05% for touching and rubbing, respectively.(82) Other 
microbial transfer studies for porous surfaces have shown similar results. For example, 
Rusin et al. reported transfer efficiencies for a bacterium, Micrococcus luteus, of 0.13% 
from a 100% cotton substrate and 0.06% from a 50:50 cotton/polyester substrate. Even 
lower transfer efficiencies (<0.01%) from those surfaces were reported for bacteriophage 
PRD-1.(83) Another recent study compared the transfer efficiency of bacteria and viruses 
from several porous and nonporous surfaces to the fingers. (84) In general, the lowest 
transfer efficiencies were found for porous surfaces under low relative humidity. Isoelectric 
point and hydrophobicity of the surface were also important factors.
As discussed previously, CFFR can be estimated. For simplicity, we use the influenza values 
reported above from Fisher et al. as a surrogate for all respiratory pathogens.(52) The contact 
area of the hands depends upon the action of the HCW (Table III). For extended use, it is 
likely that only the finger tips are used to touch the FFR surface (e.g., to reposition the FFR). 
The total surface area of the volar portion of the fingertips has been estimated to be 7.34 
cm2.(85) However, when implementing FFR reuse, the proper donning process requires a 
user seal check step, which requires the user to cover the entire FFR surface by cupping both 
hands around the filter surface. In this situation, Ah would be very similar to AFFR, which 
has been estimated to be approximately 175 cm2, but varies among the various FFR models. 
Assuming uniform deposition of the pathogen over the surface of the FFR, applying input 
values of 4,500 FFR–1 for CFFR and 0.1% as an approximation for Et to the equation results 
in an estimated 4.5 pathogens being transferred to the hands of the HCW during the user seal 
check step and <1 pathogen for each touch involving a fingertip.
Summary—While the model above indicates that some pathogens from a contaminated 
FFR could transfer to the hands, other factors also affect the risk of infection. Steps in the 
fomite pathway such as the transfer of viable pathogens from hands to respiratory tract ports 
of entry, transport of viable pathogens to the site of infection, and the infectious dose of the 
pathogen are not unique to extended use and reuse of FFRs, but are common to any potential 
fomite. A full assessment that takes into account these steps is beyond the scope of this 
commentary. However, the model developed by Nicas and Sun indicates that each 
successive step in the fomite pathway further reduces the number of infectious pathogens 
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reaching the site where infection can occur, reducing the risk of self-inoculation from 
practicing FFR extended use and/or limited reuse.(51)
In theory, extended use should not present a significant self-inoculation hazard, as ideally, 
the HCW's hands should never come in contact with the contaminated filtering surface when 
proper doffing protocols are followed.(86) However, the Rebmann study(47) reported that 
HCWs touched or adjusted their FFR on average 10–20 times per 12 hr. shift. Even with this 
amount of contact, our analysis, based on the data and the models discussed above, suggests 
that very few pathogens are likely to make it to the site of infection each time the hand or 
fingertip comes in contact with the FFR. Thus, extended use is considered minimal risk for 
typical patient interactions (Table II) when coupled with training and education to reinforce 
proper use (e.g., don't touch the FFR surface) and adherence to hand hygiene 
recommendations.
Reusing FFRs provides multiple opportunities for the hands of HCWs to come in contact 
with any infectious microbes on the respirator surface and thus involves a higher level of 
risk compared to extended use (Table II). HCWs' hands would presumably contact the 
contaminated FFR surface when placing the FFR onto the face, adjusting the position of the 
FFR and flexible strap across the nasal bridge (if applicable), and when performing the user 
seal check, a requirement after donning a respirator and after each adjustment to the 
respirator. Similar to extended use, fomite risks from FFR reuse can be mitigated through 
training and education to reduce unnecessary touching of the FFR and rigorous adherence to 
hand hygiene. Steps to limit FFR contamination (e.g., masking patients, use of engineering 
controls, face shields, and so on) can also limit fomite risks, as Chand is proportional to 
CFFR.
Risk to Others (secondary exposures)
Concerns have been raised that extended use of FFRs could result in additional opportunities 
for pathogen transmission to co-workers and patients due to reaerosolization of trapped 
pathogens to the environment from a sneeze, cough, or through rough handling. Several 
studies have addressed this issue. Most recently, Fisher et al. examined virus 
reaerosolization from FFRs and concluded that the risk of virus transfer to the environment 
from the FFR was negligible, a finding key to extended use and reuse.(87) FFRs were 
challenged with virus-containing droplet nuclei with a size range of 0.65 to 7.0 μm (with the 
majority <1.1 μm) and challenged with reversed airflow to simulate a sneeze or cough. The 
highest reaerosolization of 0.21% occurred with a droplet nuclei challenge while a droplet 
challenge led to reaerosolization of less than 0.0001%. These findings are consistent with 
earlier studies that examined reaerosolization of bacteria and inert particles. Qian et al. and 
Willeke and Qian reported the reaerosolization of less than 0.2% for bacteria deposited on 
N95 FFRs as aerosols and challenged with a reverse airflow consistent with a violent sneeze 
or cough.(88,89) Kennedy and Hines found that less than 0.3% of polystyrene latex 
microspheres reaerosolized from FFRs when dropped from a height of 3 feet(90) while 
Birkner et al reported the average release of 0.006% polystyrene latex microspheres were 
released from FFRs dropped from heights up to 1.37 m.(91)
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Overall, these data provide evidence that the risks of secondary exposure due to 
reaerosolization or rough handling associated with FFR extended use or limited reuse can be 
considered negligible (Table II). Similar to the fomite concerns discussed above, secondary 
exposure risks could increase as CFFR, the number of pathogens on the FFR, increases (i.e., 
higher CFFR = higher levels of reaerosolized pathogen), so steps taken to limit FFR 
contamination (e.g., masking patients, faceshields, local exhaust ventilation systems) should 
be implemented where possible.
In situations where patients are under contact precautions, such as those co-infected with 
common health care pathogens with the ability for prolonged environmental survival (e.g., 
Vancomycin-resistant enterococci, Clostridium difficile, and norovirus), it may be prudent to 
have HCWs discard FFRs after close contact because these pathogens could be transferred 
to other patients via the unclean hands of the HCW.
Sharing FFRs among HCWs could also result in a secondary risk if at least one of the users 
is infectious (symptomatic or asymptomatic). For example, a specialized face mask 
containing electret filter media (similar to those found in N95 FFRs) was worn in one 
study (92) to successfully collect infectious virus from the exhaled breath of symptomatic test 
subjects. Because of respirators' ability to trap respiratory pathogens, sharing a contaminated 
FFR could result in disease transmission. However, proper labeling, training, and education 
can be effective at limiting any inadvertent sharing of FFRs during reuse.
Other Regulatory and Policy Considerations
We also conducted an Internet search and reviewed FFR extended use and reuse 
recommendations issued by other United States agencies (e.g., FDA and OSHA) and 
professional organizations (e.g., Association for Professionals Infection Control and 
Epidemiology).(93,94) In terms of FFR extended use and limited reuse, we identified no 
major discrepancies among the recommendations from the Association for Professionals in 
Infection Control and Epidemiology (APIC), OSHA, and the CDC recommendations in 
(Table I). For example, OSHA TB guidance(7,95) indicates that disposable respirators (i.e., 
FFRs) can be reused by the same HCW, as long as the functional and structural integrity of 
the respirator is maintained and the outside of the filter is inspected before each use for signs 
of physical damage or soiling, and discarded if signs are present.
While OSHA is responsible for regulating employers to provide a safe workplace for their 
employees and CDC makes public health recommendations that are often adopted by 
hospitals, FDA has a different role in health care settings. The FDA regulates the 
manufacture and labeling of medical devices.(96) Medical devices are cleared by the FDA 
under the Food, Drug, and Cosmetic Act based upon data submitted by the manufacturer to 
support the claimed intended use of the product. Under 21 CFR 878.4040, FDA classifies 
surgical N95 respirators as a type of surgical apparel, intended to be worn by operating room 
personnel during surgical procedures to protect both the surgical patient and the operating 
room personnel from transfer of microorganisms, body fluids, and particulate material. As 
part of the labeling requirement, FDA recommends that manufacturers state whether a 
device is intended to be a reusable device or a single-use disposable device.(9)
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Some surgical N95 respirator models are cleared by the FDA with claims of being a single-
use device, while other manufacturers do not make such claims.(10) For surgical N95 
respirators labeled as “single use only,” extended use or limited reuse could be considered as 
an “off label” use of these products. FDA has specific requirements for reuse 
(“reprocessing”) of single-use medical devices.(97) Unfortunately, as discussed earlier in this 
manuscript, some hospital use practices for these types of medical devices such as limited 
FFR reuse were first recommended(4–7) and put into practice prior to FDA's involvement. 
There is also a general lack of awareness among infection control professionals and safety/
employee health administrators in understanding FDA's role in regulating surgical N95 
respirators.(98) These factors contribute to the prevalence of “industrial N95 FFRs” used in 
health care settings. These industrial N95 FFRs are NIOSH-certified FFRs, but have not 
been cleared by the FDA as medical devices. Several of these industrial N95 FFRs were 
stockpiled by the CDC in the Strategic National Stockpile.(99)
In the future the different regulatory and policy perspectives will need to be factored into 
FFR extended use and limited reuse recommendations. For example, recommendations for 
operating rooms, where soiling and potential contamination from blood borne pathogens 
will likely occur, might be different. In those situations, limited reuse should only be 
considered after consultation with the surgical N95 respirator manufacturer and local 
hospital infection professionals.
Knowledge Gaps
While significant progress has been made since 2006, some knowledge gaps remain to be 
filled further enhancing an understanding of the risks involved with FFR extended use and 
limited reuse. Various models related to fomite transfer were presented where little 
experimental data are available for use as inputs. In particular, data on actual FFR 
contamination levels from various health care situations and transfer efficiency of pathogens 
from FFRs to the hands are limited. While several papers have been published on 
survivability of various respiratory pathogens on FFRs and the effectiveness of antimicrobial 
technologies, it is not known how generalizable the results are, which makes it difficult to 
fully assess risk. Well-designed and carefully controlled studies carried out using consistent 
test methods appropriate to FFR reuse might reduce some of these uncertainties.
Moreover, the infectious dose of various pathogens for the various transmission routes is not 
well understood, an issue further complicated by newly emerging pathogens and strains. 
Research and development efforts such as Project BREATHE (Better Respiratory 
Equipment using Advanced Technology for Health care Employees)(3) that promote the 
development of better respirators for health care workers are needed to identify novel 
technologies and designs (e.g., launderabilty, a “no touch” user seal check, and so on) to 
address some of the additional concerns posed by extended use and reuse. The paucity of 
data on many of the practical aspects of FFR extended use and reuse also suggests that 
additional studies are needed to validate preliminary findings regarding the acceptable 
number of donnings and to develop best practices for storage, labeling, and education/
training. Surveillance data on FFR usage, including extended use and reuse, during routine 
operations and public health emergencies are needed to better understand the possible 
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benefits (e.g., cost savings, ability to extend existing supplies, reducing the “burn rate,” and 
so on) of FFR extended use and limited reuse.
Limitations
The primary purpose of this article is to assess recent scientific findings to assist policy 
makers when making decisions on whether to recommend that employers in health care 
settings permit FFR extended use and/or limited reuse during routine operations and for 
future public health emergencies. The authors acknowledge that the evidence discussed 
above is not always as sufficient as desired to develop evidence-based policy decisions. 
However, decisions on how to protect exposed workers must be made in the present and 
cannot wait until additional evidence is available. In the interim the available evidence can 
be useful for policy-based and pragmatic public health decision ideologies.(100) As discussed 
by Rosella and coauthors, (100) emerging public health situations require a balance between 
various factors. Both evidential and policy considerations are important. Policy makers need 
to use the best evidence available to them, even when it has substantial limitations, 
acknowledge the uncertainties, and account for them in as practical a way as possible.
Conclusion
For recommending FFR extended use and/or limited reuse for routine events, policy makers 
should weigh the increased risks for disease transmission from FFR extended use and 
limited reuse against the inconvenience, cost, and waste of single use. In public health 
emergencies, policies on FFR extended use and limited reuse should weigh the risks for 
disease transmission against the risk of disease transmission associated with sacrificing 
because of FFR shortages (e.g., foregoing respiratory protection or using surgical masks for 
pathogens or activities where N95 FFRs are recommended). Decisions regarding whether 
FFR extended use or limited reuse should be recommended need to continue to be pathogen-
and event-specific. The two most important factors driving this decision should be whether 
the pathogen is likely to spread (in part) via contact transmission and whether the event 
could result in or is currently causing a FFR shortage.
This analysis of recent research (post-2006) generally supports CDC guidance issued since 
2004 for FFR extended use and limited reuse for routine events such as TB and seasonal 
influenza (during AGP) as well as the public health emergencies such as the 2004 SARS and 
2009 H1N1 flu pandemics. While recent findings largely support these CDC 
recommendations, some new cautions and limitations should be considered in 
recommendations issued in the future as discussed subsequently.
Extended use offers a lower risk of self-inoculation compared to limited reuse given that the 
HCWs hands should ideally rarely contact the contaminated FFR surface. Training and 
education should be stressed to reinforce the need for strict adherence to guidance to 
minimize unnecessary contact with the FFR surface and strict adherence to hand hygiene 
practices. Extended use poses no additional health risk to a medically cleared respirator user 
and despite the additional discomfort should be tolerable for most HCWs. For these reasons, 
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extended use should be preferred over limited reuse, even though FFR reuse requires the 
least change to current practices.
Limited FFR reuse would allow the HCW to doff the FFR to provide a brief respite from the 
psychological and physiological factors that decrease FFR comfort, but increases the 
potential for contact transfer when donning the used FFR and performing the user seal 
check. However, fomite transfer models indicate that the potential for transfer of pathogens 
from FFRs to the hands of the wearer is small suggesting that limited FFR reuse can be 
employed with minimal additional risk in most cases. An exception is reuse of FFRs after 
AGPs, where higher FFR contamination levels are likely to occur. Education and training 
should be emphasized to reinforce the need for proper hand hygiene when redonning the 
FFR, including inspection of the device for physical damage and performing a user seal 
check. Strict adherence to these steps should further reduce the potential to transfer virus 
from the hands to the points of entry of infection.
While limited FFR reuse remains a viable option for reducing usage rates and for situations 
involving a pathogen that does not spread via contact transmission, data suggest that FFR 
protection can begin to be reduced for some models after multiple donnings or uses. 
Guidance should emphasize the need for the employer to consult with the respirator 
manufacturer regarding the maximum number of donnings or uses suggested for the FFR 
models used in that location or to presumptively limit the number of reuses to no more than 
five to ensure an adequate safety margin, in the absence of new information to the contrary.
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Photograph of a NIOSH certified N95 FFR cut open to show the different layers. A, 
polypropylene material (outermost layer); B, electret filtering medium (typically made from 
melt-blown or electrospun polypropylene); and C, polypropylene material (innermost layer).
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Table I
Current and Past CDC Recommendations for Limited Reuse and Extended Use of FFRs 
in Health Care for Select Respiratory Pathogens
Respiratory pathogen Contact precautions Possibility of contact 
transmissionA




TB No No No Yes
SARS Yes Yes Yes Yes
Avian Influenza A (H5N1) Yes Yes No No
2009 H1N1 Flu No Yes Yes Yes
Seasonal Influenza (AGP Only) No Yes No No
Avian Influenza A(H7N9) Yes Yes No NoB
A
The scientific community continues to debate the primary mode(s) of transmission for many respiratory viruses. However, most experts 
acknowledge that contact transmission cannot be ruled out.(101)
B
Interim recommendation, subject to change
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Table II
Qualitative Assessment of Increased Risks of FFR Extended Use and Limited Reuse 
Compared with Single Use
Issue FFR Extended Use Limited FFR Reuse
FFR Protection • Negligible risk of decreased protection • Minimal risk of decreased protection, but can be 
mitigated through limiting the number of reuses.
Human Factors • Increased discomfort, but no additional 
health risk to a medically cleared respirator 
user
• No additional health risk to a medically cleared 
respirator user
Self-inoculation • Minimal risk for typical patient 
interactions, but can be mitigated through 
training and education
• Risks can increase during/after AGP but 
can be reduced by limiting contamination
• Moderate risk for typical patient interactions but 
can be mitigated through training and education 
and limiting the number of reuses
• Risks can increase during/after AGP but can be 
reduced by limiting contamination
Secondary Exposures • Negligible for typical patient interactions
• Minimal following AGP but can be 
reduced by limiting contamination
• Negligible for typical patient interactions
• Minimal following AGP but can be reduced by 
limiting contamination
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Table III
Steps in the Donning and Doffing Process Involving Potential Contact with FFR Surface
Strategy Donning User Seal Check Doffing
FFR Reuse Yes Yes NoA
FFR Extended Use No No NoA
A
HCWs hands should not contact the surface if proper doffing technique is used.
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